Judge Blocks Colorado’s Enbrel Price Cap in Federal Ruling

What happens to the folks in Delta who rely on Enbrel when the state’s bold experiment with price caps hits a federal wall? That’s the question hanging over the Western Slope this week, right after Chief Judge Daniel D. Domenico of the U.S. District Court in Denver issued a preliminary injunction that temporarily blocks Colorado’s first-in-the-nation price cap on the autoimmune drug. It’s a significant blow to Governor Jared Polis and his administration’s strategy to tame runaway healthcare costs, and it leaves the state’s Prescription Drug Affordability Board, or PDAB, wondering how to proceed with its mandate.

The ruling doesn’t just stop a number on a page; it halts a mechanism designed to make life bearable for thousands of Coloradans managing rheumatoid arthritis and other autoimmune conditions. Enbrel, manufactured by Amgen, carries a wholesale cost of about $96,000 per patient per year. But if you look closely at the actual transactions, the picture is more complex. After discounts and rebates are applied, most patients and insurance companies combined pay roughly $58,000 per patient per year. The PDAB, determined that even that adjusted price was too steep for the average family, set a new cap at around $31,000 per year, scheduled to take effect in 2027.

Now, that $31,000 figure is frozen in legal limbo.

Amgen sued, arguing that the cap undermines federal patent law and would cause the company economic harm. Judge Domenico agreed, citing binding precedent from the U.S. Court of Appeals for the Federal Circuit. He pointed to a similar effort by the District of Columbia, where appellate courts ruled that price controls on patented drugs were preempted by federal law. The logic is a trade-off: to encourage research, development, and innovation, the government grants drug companies a temporary monopoly, allowing them to charge whatever they want to recoup their R&D costs. “Colorado’s attempt to rebalance Congress’s patent system is preempted by federal law,” Domenico wrote.

For locals, this isn't just about abstract legal theory. It’s about whether the state can force a pharmaceutical giant to lower prices without running afoul of the federal government’s own rules. The state had argued that the pharmaceutical industry’s pricing system is so complicated and opaque that consumers have no choice but to pay the premium. But the judge’s ruling suggests that the federal patent system, not the state, holds the keys to the kingdom.

The injunction blocks the cap from taking effect while the lawsuit is debated, meaning Amgen can continue to charge its current rates for now. This is a temporary pause, not a final verdict, but it raises serious questions about the ongoing operations of the PDAB. If the state’s primary tool for affordability is blocked, what’s next? Will they try again, or will they have to find a different lever to pull?

You can feel the weight of that uncertainty in the pharmacy lines across the valley. People waiting for their prescriptions aren't thinking about federal patent law or the intricacies of the 10th Circuit Court of Appeals. They’re thinking about whether their insurance will cover the next injection, and whether the $31,000 cap they were promised will ever actually materialize. The judge, appointed by President Donald Trump and currently up for a promotion to the 10th Circuit, has drawn a line in the sand. For now, Amgen stands firm, and the state has to decide if it’s worth the drive to challenge it.

Outside the Amgen headquarters in Thousand Oaks, California, the signage remains unchanged, a quiet reminder of the corporate power at play. But here in Colorado, the waiting continues, the receipts keep piling up, and the question of who really controls the price of health remains unanswered.